Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are undergoing heart surgery as the lead indication. We walk through various scenarios ahead of the upcoming readout.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.